Section Arrow
Quote
PRAX.NASDAQ
- Praxis Precision Medicines
Quotes are at least 15-min delayed:2026/09/06 08:56 EDT
Regular Hours
Last
 351.81
-3.34 (-0.94%)
Day High 
357.5 
Prev. Close
355.15 
1-M High
392.7 
Volume 
175.36K 
Bid
335
Ask
375
Day Low
349.8182 
Open
352.99 
1-M Low
301.4 
Market Cap 
9.92B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 361.84 
20-SMA 366.77 
50-SMA 338.63 
52-W High 392.7 
52-W Low 37.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.96/-7.54
Enterprise Value
9.92B
Balance Sheet
Book Value Per Share
48.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.07
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.8+0.69+62.16%-- 
RXRXRecursion Pharmaceuticals3.63+0.19+5.52%-- 
CMNDClearmind Medicine Inc.1.16-0.54-31.76%-- 
MRNAModerna145.55-3.32-2.23%-- 
RAREUltragenyx Pharmaceutical15.3+0.45+3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.